Three Seasons Wealth LLC Takes Position in Exelixis, Inc. $EXEL

Three Seasons Wealth LLC purchased a new position in Exelixis, Inc. (NASDAQ:EXEL) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 28,276 shares of the biotechnology company’s stock, valued at approximately $1,168,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in EXEL. Comerica Bank raised its holdings in shares of Exelixis by 1.2% in the 1st quarter. Comerica Bank now owns 88,723 shares of the biotechnology company’s stock worth $3,276,000 after buying an additional 1,042 shares in the last quarter. Landscape Capital Management L.L.C. grew its position in Exelixis by 286.1% in the first quarter. Landscape Capital Management L.L.C. now owns 23,427 shares of the biotechnology company’s stock valued at $865,000 after acquiring an additional 17,360 shares during the period. Canada Pension Plan Investment Board raised its stake in Exelixis by 48.2% during the first quarter. Canada Pension Plan Investment Board now owns 642,400 shares of the biotechnology company’s stock worth $23,717,000 after acquiring an additional 209,000 shares in the last quarter. Quarry LP raised its stake in Exelixis by 4,900.0% during the first quarter. Quarry LP now owns 2,000 shares of the biotechnology company’s stock worth $74,000 after acquiring an additional 1,960 shares in the last quarter. Finally, Graham Capital Management L.P. lifted its holdings in shares of Exelixis by 6.0% during the first quarter. Graham Capital Management L.P. now owns 21,020 shares of the biotechnology company’s stock valued at $776,000 after acquiring an additional 1,199 shares during the period. Institutional investors own 85.27% of the company’s stock.

Analyst Upgrades and Downgrades

EXEL has been the topic of several analyst reports. TD Cowen upped their target price on shares of Exelixis from $44.00 to $51.00 and gave the stock a “buy” rating in a report on Wednesday, November 5th. UBS Group upped their price objective on shares of Exelixis from $35.00 to $40.00 and gave the stock a “neutral” rating in a research note on Thursday, November 6th. Wells Fargo & Company dropped their price objective on shares of Exelixis from $36.00 to $30.00 and set an “equal weight” rating for the company in a report on Tuesday, October 21st. Barclays boosted their target price on Exelixis from $40.00 to $41.00 and gave the stock an “equal weight” rating in a report on Wednesday, November 5th. Finally, The Goldman Sachs Group began coverage on Exelixis in a research report on Wednesday, September 17th. They set a “buy” rating and a $47.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and eleven have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $45.74.

Insider Transactions at Exelixis

In other Exelixis news, Director Mary C. Beckerle sold 24,622 shares of the business’s stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $41.93, for a total transaction of $1,032,400.46. Following the completion of the sale, the director directly owned 21,380 shares of the company’s stock, valued at approximately $896,463.40. The trade was a 53.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Stelios Papadopoulos sold 100,000 shares of Exelixis stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $43.55, for a total transaction of $4,355,000.00. Following the sale, the director owned 1,189,228 shares of the company’s stock, valued at approximately $51,790,879.40. This represents a 7.76% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 245,235 shares of company stock valued at $10,490,600 in the last three months. Company insiders own 2.85% of the company’s stock.

Exelixis Price Performance

EXEL stock opened at $46.24 on Monday. The company has a 50 day moving average price of $41.82 and a 200 day moving average price of $40.93. Exelixis, Inc. has a fifty-two week low of $31.90 and a fifty-two week high of $49.62. The stock has a market capitalization of $12.40 billion, a PE ratio of 19.51, a price-to-earnings-growth ratio of 0.83 and a beta of 0.40.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.68 by $0.10. The firm had revenue of $597.76 million for the quarter, compared to analyst estimates of $590.04 million. Exelixis had a return on equity of 31.06% and a net margin of 29.63%.The business’s quarterly revenue was up 10.8% compared to the same quarter last year. During the same period last year, the company earned $0.47 EPS. As a group, equities analysts expect that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Exelixis Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.